Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
December 28, 2023
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7
Sabine Heublein, Jacobus Pfisterer, Andreas du Bois, et al.
International Journal of Cancer
|
May 18, 2010
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Markus M Heiss, Pawel Murawa, Piotr Koralewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
Journal of Medical Genetics
|
December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i>: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Philipp Harter, Corinna Ernst, et al.
International Journal of Cancer
|
August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Florian Heitz, Stefan Kommoss, Roshan Tourani, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2017
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, et al.
The New England Journal of Medicine
|
December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
December 28, 2023
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7
Sabine Heublein, Jacobus Pfisterer, Andreas du Bois, et al.
International Journal of Cancer
|
May 18, 2010
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Markus M Heiss, Pawel Murawa, Piotr Koralewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
Journal of Medical Genetics
|
December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i>: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Philipp Harter, Corinna Ernst, et al.
International Journal of Cancer
|
August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Florian Heitz, Stefan Kommoss, Roshan Tourani, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2017
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, et al.
The New England Journal of Medicine
|
December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Page
of 12